Insights
Statistical analysis and insight into activity and trends in M&A and capital markets.

Recent Investment Banking Insights
The Quarterly Rx: 2022 Year in Review U.S. Biopharma Recap
After an undoubtedly challenging year for the biopharma sector in which macroeconomic risk weighed on investor sentiment, we began to see signs of stability to close out 2022 – prompting increased optimism for a recovery in 2023.
Read moreThree Phases of Growth in Three Years—Private Label’s Continued Evolution
As inflation puts pressure on consumer spending, private label food and beverage is well positioned and has regained the momentum it lost during the COVID-19 pandemic.
Read moreStructured Equity Solutions: Capital for Growth, Tuck-In Acquisitions, and Shareholder Liquidity
The IPO window has narrowed and debt markets have tightened, but options exist for growing companies looking to raise capital.
Read moreFacility and Asset Management Software: Sustainable Infrastructure Technology for the Built-World
Renewed focus on facility and asset management software as market participants turn to software to address the mission-critical operational, planning, and energy consumption needs of the built-world.
Read moreNavigating Today’s Rising Rate Environment
Today’s debt markets are evolving quickly in reaction to the current macroeconomic backdrop, hawkish fed, and inflationary environment. The leveraged finance markets remain largely receptive despite rising levels of uncertainty.
Read moreUnderstanding the Nuances of Full/Partial Company Sales
Executives considering selling their business have a lot to think about, from the possible purchase price to how employees and the broader community might be affected.
Read moreLeverage Finance Activity Slows in Q3 Amidst Rising Interest Rates and Sustained Macroeconomic Volatility
Institutional loan volume came to a screeching halt in the third quarter, reaching its lowest quarterly total in over 10 years, as broadly syndicated debt and M&A markets were stymied by rising interest rates and macroeconomic challenges.
Read moreKey Themes for Public Company Board Agendas to Close Out 2022
William Blair’s Corporate Advisory team examines how shifts in the equity markets, macroeconomic environment, and M&A landscape are affecting public company board agendas for the remainder of the year.
Read morePropTech Sector Sees Growing M&A Interest as Macro Trends Reshape Real Estate Market
Technological innovation is disrupting the residential real estate sector as investors and innovative companies seek to address all parts of the homebuying value chain and improve the experience of both real estate agents and consumers.
Read moreThe Quarterly Rx: Q3 2022 U.S. Biopharma Recap
While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term.
Read moreGeneral Aviation Has Staying Power. So Does M&A Activity Among Fixed Base Operators
A rebound that started in the second half of 2020 portends good things for general aviation and the fixed base operators (FBO) that serve the nation’s airports—even in the face of broader economic headwinds.
Read more